Partner Content Partner Content How to Provide Value that Benefits Patients (and Your Brand) Identify opportunities by condition or therapeutic area
R&D Understanding the microbiome as an ‘overlooked critical orga... Compared to a ‘critical organ’ that had been largely ignored, companies working to develop microbiome-based therapies believe there is untapped potential in the area.
Events Partner Content Next Generation RNA Therapeutics Summit Trailblazing Superior RNA Therapeutics of the Future
Partner Content Partner Content KOL Identification & Mapping Driven By Insights Insights captured from KOL interactions represent a new way to identify and map the KOL landscape in which your brand must thrive.
Events Partner Content 3rd Gamma Delta T Therapies Summit The Only Industry-Specific Event on γδT Therapies
Views & Analysis Independent health comms agencies rebrand with emphasis on a... In a world of a million messages, should authenticity be the common thread tying all pharma communications and marketing activities together?
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
